Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Nature Genetics

• Publication date

  2022-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41588-022-01108-wPMID 35817971PMCID PMC10181095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

  2021cited by this paper
• Improved prediction of immune checkpoint blockade efficacy across multiple cancer types

  2021cited by this paper
• Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

  2021cited by this paper
• Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor

  2021cited by this paper
• TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response

  2021cited by this paper
• Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers

  2021cited by this paper
• Mutational signatures: emerging concepts, caveats and clinical applications

  2021cited by this paper
• dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs

  2020cited by this paper
• A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.

  2020cited by this paper
• The association between tumor mutational burden and prognosis is dependent on treatment context

  2020cited by this paper
• Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

  2020cited by this paper
• Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

  2020cited by this paper
• Sequence Analysis

  2020cited by this paper
• Top 10 Challenges in Cancer Immunotherapy.

  2020cited by this paper
• DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden

  2020cited by this paper
• Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.

  2019cited by this paper
• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  2019cited by this paper
• Novel patterns of response under immunotherapy

  2019cited by this paper
• CRISPResso2 provides accurate and rapid genome editing sequence analysis

  2019cited by this paper
• Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis

  2019cited by this paper
• Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response

  2019cited by this paper
• Next-generation characterization of the Cancer Cell Line Encyclopedia

  2019cited by this paper
• Interpretation of somatic POLE mutations in endometrial carcinoma

  2019cited by this paper
• SigProfilerMatrixGenerator: a tool for visualizing and exploring patterns of small mutational events

  2019cited by this paper
• Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma

  2019cited by this paper
• Structure Based Prediction of Neoantigen Immunogenicity

  2019cited by this paper
• Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1.

  2019cited by this paper
• Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

  2019cited by this paper
• Complete and Prolonged Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal Cancer.

  2019cited by this paper
• Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology

  2019cited by this paper
• DNA repair defects and implications for immunotherapy.

  2018cited by this paper
• TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis

  2018cited by this paper
• Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load

  2018cited by this paper
• Strelka2: fast and accurate calling of germline and somatic variants

  2018cited by this paper
• The Immune Landscape of Cancer.

  2018cited by this paper
• Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

  2018cited by this paper
• Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

  2018cited by this paper
• The repertoire of mutational signatures in human cancer

  2018cited by this paper
• DNA Damage and Repair Biomarkers of Immunotherapy Response.

  2017cited by this paper
• xCell: digitally portraying the tissue cellular heterogeneity landscape

  2017cited by this paper
• Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

  2017cited by this paper
• Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

  2017cited by this paper
• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

  2017cited by this paper
• Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy.

  2017cited by this paper
• Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients

  2017cited by this paper
• Comprehensive Analysis of Hypermutation in Human Cancer.

  2017cited by this paper
• OncoKB: A Precision Oncology Knowledge Base.

  2017cited by this paper
• POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer

  2017cited by this paper
• RECIST 1.1-Update and clarification: From the RECIST committee.

  2016cited by this paper
• Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

  2016cited by this paper
• deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution

  2016cited by this paper
• The Ensembl Variant Effect Predictor

  2016cited by this paper
• Mouse models in oncoimmunology

  2016cited by this paper
• A panoply of errors: polymerase proofreading domain mutations in cancer

  2016cited by this paper
• DNA Polymerases Divide the Labor of Genome Replication.

  2016cited by this paper
• MutationalPatterns: comprehensive genome-wide analysis of mutational processes

  2016cited by this paper
• FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

  2016cited by this paper
• Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.

  2016cited by this paper
• Complex heatmaps reveal patterns and correlations in multidimensional genomic data

  2016cited by this paper
• Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

  2015cited by this paper
• POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance

  2015cited by this paper
• TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• MiXCR: software for comprehensive adaptive immunity profiling

  2015cited by this paper
• The UCSC Genome Browser database: 2015 update

  2014cited by this paper
• Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

  2014cited by this paper
• MSIsensor: microsatellite instability detection using paired tumor-normal sequence data

  2014cited by this paper
• Multiplex Genome Engineering Using CRISPR/Cas Systems

  2013cited by this paper
• Genome engineering using the CRISPR-Cas9 system

  2013cited by this paper
• STAR: ultrafast universal RNA-seq aligner

  2013cited by this paper
• Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

  2013cited by this paper
• Properties of MHC Class I Presented Peptides That Enhance Immunogenicity

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Software for Computing and Annotating Genomic Ranges

  2013cited by this paper
• clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

  2012cited by this paper
• SomaticSniper: identification of somatic point mutations in whole genome sequencing data

  2012cited by this paper
• International network of cancer genome projects

  2010cited by this paper
• The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

  2010cited by this paper
• DNA polymerase ε and δ proofreading suppress discrete mutator and cancer phenotypes in mice

  2009cited by this paper
• Evolving views of DNA replication (in)fidelity.

  2009cited by this paper
• VarScan: variant detection in massively parallel sequencing of individual and pooled samples

  2009cited by this paper
• GenePattern 2.0

  2006cited by this paper
• Theoretical and practical advances in genome halving

  2004cited by this paper
• Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

  1999cited by this paper
• A simple method for displaying the hydropathic character of a protein.

  1982cited by this paper
• A colon tumor model for anticancer agent evaluation

  1975cited by this paper
• Amino Acid Difference Formula to Help Explain Protein Evolution

  1974cited by this paper
• Index for rating diagnostic tests

  1950cited by this paper

• Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation.

  2026cites this paper
• Innate immunity in tumour immunoediting and immunosurveillance

  2025cites this paper
• PPP2R1A Mutation: A Critical Amplifier for Immune Checkpoint Blockade Therapy Efficacy

  2025cites this paper
• Genome instability and crosstalk with the immune response

  2025cites this paper
• Leveraging oncology clinical case report data through the Cancer Knowledgebase (CKB).

  2025cites this paper
• Deficiency in POLE exonuclease causes synthetic lethality in highly aneuploid cancer cells

  2025cites this paper
• POLD1 identification as a potential prognostic and immunotherapeutic biomarker for hepatocellular carcinoma.

  2025cites this paper
• Comprehensive Analysis of Human Colorectal Cancers Harboring Polymerase Epsilon Mutations

  2025cites this paper
• Updates of CSCO guidelines for colorectal cancer version 2025.

  2025cites this paper
• Beyond proofreading: POLD1 mutations as dynamic orchestrators of genomic instability and immune evasion in cancer

  2025influential citation
• Unveiling ctDNA Response: Immune Checkpoint Blockade Therapy in a Patient with POLE Mutation-Associated Early-Onset Colon Cancer

  2025cites this paper
• AlphaMissense for Identifying Pathogenic Missense Mutations in DNA Damage Repair Genes in Cancer

  2025cites this paper
• Predictive biomarkers in the era of immunotherapy for gastric cancer: current achievements and future perspectives

  2025cites this paper
• The cold immunological landscape of ATM-deficient cancers

  2025cites this paper
• Of Context, Quality, and Complexity: Fine-combing Tumor Mutation Burden in Immunotherapy Treated Cancers.

  2025cites this paper
• Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy.

  2025cites this paper
• Helicobacter pylori infection induces DNA double-strand breaks through the ACVR1/IRF3/POLD1 signaling axis to drive gastric tumorigenesis

  2025cites this paper
• Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

  2025cites this paper
• Molecular features and clinical actionability of gene fusions in colorectal cancer.

  2025cites this paper
• Five latent factors underlie response to immunotherapy

  2024cites this paper
• DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors

  2024cites this paper
• The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway

  2024cites this paper
• An immunogenetic basis for lung cancer risk

  2024cites this paper
• Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer

  2024cites this paper
• Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer.

  2024cites this paper
• A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer

  2024cites this paper
• Deep Learning Based on Computed Tomography Predicts Response to Chemoimmunotherapy in Lung Squamous Cell Carcinoma

  2024cites this paper
• Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency

  2024cites this paper
• Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure

  2024cites this paper
• CSCO guidelines for colorectal cancer version 2024: Updates and discussions.

  2024cites this paper
• Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms

  2024cites this paper
• A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation

  2024cites this paper
• Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer.

  2024cites this paper
• Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes

  2024cites this paper
• The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update

  2024cites this paper
• Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?

  2023cites this paper
• Prospects of POLD1 in Human Cancers: A Review

  2023cites this paper
• From Cue to Meaning: The Involvement of POLD1 Gene in DNA Replication, Repair and Aging.

  2023cites this paper
• Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden

  2023cites this paper
• Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

  2023cites this paper
• Integrating POLE / POLD1 mutated for immunotherapy treatment planning of advanced stage non‐small cell lung cancer

  2023cites this paper
• Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy

  2023cites this paper
• Dissecting metastasis using preclinical models and methods

  2023cites this paper
• DNA damage repair and cancer immunotherapy

  2023cites this paper
• Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes

  2023cites this paper
• Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.

  2023cites this paper
• Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

  2023cites this paper
• Mutational signature assignment heterogeneity is widespread and can be addressed by ensemble approaches

  2023cites this paper
• Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

  2023cites this paper
• Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation

  2023cites this paper
• Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions

  2023cites this paper
• Biomarkers and experimental models for cancer immunology investigation

  2023cites this paper
• POLD1 DEDD Motif Mutation Confers Hypermutation in Endometrial Cancer and Durable Response to Pembrolizumab

  2023cites this paper
• Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway

  2023cites this paper
• CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.

  2023cites this paper
• Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.

  2023cites this paper
• Experimental models for cancer brain metastasis

  2023cites this paper
• Enhancing the anticancer immune response with the assistance of drug repurposing and delivery systems

  2023cites this paper
• Replication DNA polymerases, genome instability and cancer therapies

  2023cites this paper
• Proteomic Characterization of SAS Cell-Derived Extracellular Vesicles in Relation to Both BPA and Neutron Irradiation Doses

  2023cites this paper
• Pairwise and higher-order epistatic effects among somatic cancer mutations across oncogenesis

  2022cites this paper
• Potential of VEGFR2 expression as a predictive marker of PD-1 blockade in patients with advanced NSCLC

  2022cites this paper
• Tumor microenvironment: barrier or opportunity towards effective cancer therapy

  2022cites this paper
• Interpreting the Effects of DNA Polymerase Variants at the Structural Level

  year unknowncites this paper